miR-146a在乳腺浸润性导管癌中的表达及临床意义

目的观察microRNA-146a（miR-146a）在乳腺浸润性导管癌及癌旁正常对照组织中的表达,探讨miR-146a的表达与乳腺癌临床病理特征的关系及其对乳腺癌发生发展的影响。方法采用组织芯片平台,应用原位杂交方法检测65例乳腺浸润导管癌及癌旁正常对照组织中miR-146a的表达。结果乳腺浸润性导管癌miR-146a阳性率低于癌旁正常对照组织（44.6%vs 66.2%,P〈0.05）;乳腺浸润性导管癌中miR-146a的表达与淋巴结转移有关联（P〈0.01）,与患者年龄、肿瘤大小、组织学分级、TNM分期、ER、PR、c-erbB-2、ki67、p53、E-cadherin过表达均无相关性（P〉0.05）。结论 miR-146a在乳腺浸润性导管癌中表达下调,提示其可能作为重要的抑癌因子参与乳腺癌的发生发展过程,并可能成为乳腺癌新的肿瘤标记物或预后因子。

Expression of miR-146a in breast infiltrative ductal carcinoma and its clinical significance.

Objective To investigate the expression of microRNA-146a （miR-146a） in breast infiltrative ductal carcinoma and its clinicopathologie significance. Methods miR-146a expression was detected in 65 cases of breast infiltrative ductal carcinoma and corresponding paracarcinoma nomal tissues on tissue microarray sections by in situ hybridization. Results The expression rate ofmiR-146a in breast infiltrative ductal carcinoma was significantly lower than that of the paracarcinoma nomal tissues （44.6% vs 66.2%, P〈0.05）. There were positive correlations be- tween miR-146a expression and lymph node metastasis （P〈0.01）. There were no correlations between the expression of miR-146a and age, size, histological grading, TNM stage, ER and PR status, c-erbB-2 over expression, ki-67 posi- tive expression, P53 positive expression, E-cadherin positive expression. Conclusion The down-expression of miR-146a in the breast infiltrative ductal carcinoma suggests that it may be involved in tumourgenesis of breast carci- noma. miR-146a may become a novel tumormarker or prognostic factor for breast carcinoma.